Corruption Probe Could Be A Double-Edged Sword For Chinese Domestic Makers
This article was originally published in PharmAsia News
Chinese domestic pharmaceutical executives have been mostly tight-lipped about the government’s ongoing anti-corruption investigation, which has mainly targeted multinationals. But recent developments indicate that local companies may soon feel the heat.
You may also be interested in...
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.